The Wooten study has been available online since February 17 in the Gynecologic Oncology journal (pp 268 - 273). The study involved 14 patients and the investigators conclude that Cs-131 is a therapeutic option for appropriately selected patients.
According to IsoRay's March 14, 2014 prospectus supplement, the FDA approved Cs-131 for the treatment of all solid tumor applications in 2003.
Share prices emerged from their eight-year downtrend only a couple of months ago.
Retail investors should tread carefully here.